China's medical products administrator approved CSPC Pharmaceutical's (HKG:1093) drug registration for its vonoprazan fumarate acid blockers, according to a Monday filing with the Hong Kong bourse.
The drug is indicated for reflux esophagitis and for the removal of Helicobacter pylori in combination with antibiotics, the filing said.
Vonoprazan fumarate is a postassium-competitive acid blocker and reversible proton pump inhibitor that blocks gastric acid secretion, the filing said.
Shares rose 1% during afternoon trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.